I suspect the issue may be, that MSB sees mileage in impressing regulators with multiple PhII trials, across multiple disease types [ie, diabetes and RA]......and aiming for lumping all that data in and saying....."can we get some type of breakthrough/early approval please".
I'm not sure the FDA approves things on the basis of, "They are not just trying one thing; they are trying lots of things, so yeah, in that case we'll give them the green light."
"but I think RA is just about complete with its PhII now and D is done....so a decision point has been arrived at. "
I'm not sure what you mean by "D is done".
Because if it was, a decision would not take so long to make.
It's going on for 10 months since they published Phase2 trial results.
That would be long enough a time period over which to negotiate and conclude a partnership, so they must be close to announcing one, other wise as you said, it would be a pity if they dropped the ball on this one...
- Forums
- ASX - By Stock
- MSB
- Diabetes.......where are we at?
Diabetes.......where are we at?, page-8
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.07 |
Change
0.005(0.47%) |
Mkt cap ! $1.216B |
Open | High | Low | Value | Volume |
$1.08 | $1.10 | $1.06 | $3.371M | 3.135M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 45345 | $1.06 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.07 | 3875 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 45345 | 1.055 |
9 | 193430 | 1.050 |
3 | 44331 | 1.045 |
5 | 117942 | 1.040 |
3 | 53830 | 1.035 |
Price($) | Vol. | No. |
---|---|---|
1.065 | 3875 | 2 |
1.070 | 28953 | 3 |
1.075 | 46564 | 3 |
1.080 | 87551 | 5 |
1.085 | 47614 | 4 |
Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |